Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has a history of migraine with or without aura for 1 year or more with 2-8 moderate or severe migraine attacks per month~* Patient generally does not respond to treatment with sumatriptan~* Patient of reproductive potential agrees to remain abstinent or use one method of highly effective birth control (i.e. IUD, condoms, hormonal contraceptive, diaphragm, vasectomy) for the duration of the study~* Patient is able to complete paper diary~Exclusion Criteria:~* Patient is pregnant or breast feeding or excepts to become pregnant during the study~* Patient has history of mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours~* Patient has basilar or hemiplegic migraines~* Patient is unable to distinguish between migraine attacks from other types of headaches~* Patient has more than 15 headache-days per month~* Patient was greater than 50 years old at age of migraine onset~* Patient has failed to respond to 3 or more triptans~* Patient has a repeated history of failing to respond to or tolerate rizatriptan~* Patient uses opioids as primary migraine therapy~* Patient uses daily opioids~* Patient has a history of Cerebrovascular Accident (CVA) or other significant cardiovascular disease~* Patient has uncontrolled hypertension~* Patient has a history of neoplastic disease~* Patient is taking a serotonin reuptake inhibitor (SSRI or SNRI) where the dose has changed 3 months prior to screening~* Patient has a history of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Sequence A (Type: EXPERIMENTAL): Rizatriptan - Rizatriptan - Placebo
- Treatment Sequence B (Type: EXPERIMENTAL): Rizatriptan - Placebo - Rizatriptan
- Treatment Sequence C (Type: EXPERIMENTAL): Placebo - Rizatriptan - Rizatriptan
- Baseline Phase (Type: OTHER): Sumatriptan

Based on this trial design, predict the completion outcome and termination type (if applicable).